Locket Healthcare Expands into the Philippines, Thailand, and Brazil

[Asia Economy Reporter Hyungsoo Park] Rokit Healthcare is supplying its diabetic foot (diabetic foot ulcer) regeneration treatment platform to three countries: the Philippines, Thailand, and Brazil.

Rokit Healthcare announced on the 28th that its diabetic foot regeneration treatment platform is expanding overseas through 1000Medic, a medical device supplier, and SRS Life Science.

SRS Life Science, headquartered in Singapore, operates subsidiaries in six countries including the Philippines, Thailand, and Russia. Rokit Healthcare has completed medical device registration in the Philippines and Thailand and plans to begin full-scale commercialization in the second half of this year.

They have signed a supply contract with 1000Medic, a medical device supplier headquartered in Brazil. They plan to complete local regulatory approval around April this year and proceed with commercialization.

Rokit Healthcare is also entering the Chinese market. Kim Jihee, CTO of Rokit Healthcare, explained, "We are currently discussing contracts with a Chinese-based company for nationwide supply in China."

Rokit Healthcare’s regenerative treatments have been applied to diabetic foot, cartilage, and kidney treatments, with clinical trials either underway or completed. A company representative stated, "We are achieving successful results in preclinical studies on customized skin regeneration, cartilage regeneration, and kidney regeneration," adding, "We plan to expand development to regenerate various organs such as the heart, liver, and lungs."

Yoo Seokhwan, CEO of Rokit Healthcare, said, "The global diabetic foot treatment market is approximately 100 trillion KRW and is growing annually," and added, "Meaningful clinical results are emerging not only for the diabetic foot regeneration treatment platform but also for kidney and cartilage regeneration treatments."

This content was produced with the assistance of AI translation services.